

# Skyrizi® (risankizumab-rzaa) (Intravenous)

Document Number: MODA-0671

Last Review Date: 03/04/2025

Date of Origin: 07/05/2022

Dates Reviewed: 07/2022, 10/2022, 08/2023, 07/2024, 08/2024, 10/2024, 03/2025

## I. Length of Authorization

Coverage will be provided for 11 weeks (3 doses) and cannot be renewed.

## II. Dosing Limits

**Max Units (per dose and over time) [HCPCS Unit]:**

- Crohn's Disease
  - 600 billable units (600 mg) at Week 0, 4, & 8
- Ulcerative Colitis
  - 1200 billable units (1200 mg) at Week 0, 4, & 8

## III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

### ***For Commercial Members Only***

- Patients must have an inadequate response to an adequate trial of, or contraindication or intolerance to Entyvio IV (vedolizumab IV) AND Stelara (ustekinumab) or Wezlana (ustekinumab-auub) AND Cimzia (certolizumab pegol) prior to initiating therapy with Skyrizi (risankizumab); **AND**

### ***For Medicaid Members Only***

- Patients must have an inadequate response to an adequate trial of, or contraindication or intolerance to Stelara (ustekinumab) or Wezlana (ustekinumab-auub) prior to initiating therapy with Skyrizi (risankizumab); **AND**

- Patient is at least 18 years of age; **AND**
- Physician has assessed baseline disease severity utilizing an objective measure/tool; **AND**
- Patient is up to date with all age-appropriate vaccinations, in accordance with current vaccination guidelines, prior to initiating therapy; **AND**
- Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring for the presence of TB during treatment; **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**

- Patient will not receive live vaccines during therapy; **AND**
- Patient is not on concurrent treatment with another biologic therapy or targeted synthetic therapy; **AND**
- Baseline liver enzymes and bilirubin levels have been obtained prior to initiating therapy; **AND**

**Crohn’s Disease (CD) †<sup>1-6,15,16</sup>**

- Documented moderate to severe active disease; **AND**
  - Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum 3-month trial of corticosteroids or immunomodulators (e.g., azathioprine, 6-mercaptopurine, methotrexate, etc.); **OR**
  - Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum 3-month trial of a TNF modifier (e.g., adalimumab, certolizumab, or infliximab); **OR**
  - Patient has evidence of high-risk disease for which corticosteroids or immunomodulators are inadequate and biologic therapy is necessary; **OR**
  - Patient is already established on a biologic or targeted synthetic therapy for the treatment of CD

**Ulcerative Colitis †<sup>1,11-14</sup>**

- Documented moderate to severe active disease; **AND**
  - Documented failure or ineffective response to a minimum 3-month trial of conventional therapy [aminosalicylates, corticosteroids or immunomodulators (e.g., azathioprine, 6-mercaptopurine, methotrexate, etc.)] at maximum tolerated doses, unless there is a contraindication or intolerance to use; **OR**
  - Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum 3-month trial of a TNF modifier such as adalimumab, golimumab, or infliximab; **OR**
  - Patient is already established on a biologic or targeted synthetic therapy for the treatment of UC

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); ◻ Orphan Drug

**IV. Renewal Criteria <sup>1</sup>**

Duration of authorization has not been exceeded (*refer to Section I*)

**V. Dosage/Administration <sup>1</sup>**

| Indication      | Dose   |
|-----------------|--|
| Crohn’s Disease | Administer 600 mg intravenously at Week 0, Week 4, and Week 8 followed by subcutaneous maintenance therapy thereafter. |

| Indication         | Dose  |
|--------------------|---|
| Ulcerative Colitis | Administer 1200 mg intravenously at Week 0, Week 4, and Week 8 followed by subcutaneous maintenance therapy thereafter. |

## VI. Billing Code/Availability Information

HCPCS Code:

- J2327 – Injection, risankizumab-rzaa, intravenous, 1 mg; 1 billable unit = 1 mg

NDC:

- Skyrizi carton containing one 600 mg/10 mL single-dose vial: 00074-5015-xx

## VII. References

1. Skyrizi [package insert]. North Chicago, IL; AbbVie, Inc.; June 2024. Accessed January 2025.
2. D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. *Lancet*. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6.
3. Lichtenstein GR, Loftus EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol* 2018; 113:481–517; doi: 10.1038/ajg.2018.27.
4. Torres J, Bonovas S, Doherty G, et al. European Crohn's and Colitis Organisation [ECCO] Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *Journal of Crohn's and Colitis*, 2020, 4–22 doi:10.1093/ecco-jcc/ijz180.
5. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the use of Thiopurines, Methotrexate, and Anti-TNF- $\alpha$  Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease. *Gastroenterology* 2013;145:1459-1463.
6. National Institute for Health and Care Excellence. NICE 2019. Crohn's Disease: Management. Published 03 May 2019. NICE Guideline [NG129]. <https://www.nice.org.uk/guidance/ng129>.
7. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis*. 2017 Jan 28. doi: 10.1093/ecco-jcc/ijx009.
8. Lewis JD, Chuai S, Nessel L, et al. Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. *Inflamm Bowel Dis*. 2008 Dec; 14(12): 1660–1666. doi: 10.1002/ibd.20520.
9. Paine ER. Colonoscopic evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf)*. 2014 Aug; 2(3): 161–168.
10. Walsh AJ, Bryant RV, Travis SPL. Current best practice for disease activity assessment in IBD. *Nature Reviews Gastroenterology & Hepatology* 13, 567–579 (2016) doi:10.1038/nrgastro.2016.128.

11. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006.
12. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. *J Crohns Colitis*. 2022 Jan 28. 16 (1):2-17. Doi: 10.1093/ecco-jcc/jjab178.
13. Louis E, Panaccione R, Parkes G, et al. S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study. *The American Journal of Gastroenterology* 118(12S):p S2, December 2023. | DOI: 10.14309/01.ajg.0000995752.19097.c8
14. Louis E, Panaccione R, Parkes G, et al. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study, *Journal of Crohn's and Colitis*, Volume 18, Issue Supplement\_1, January 2024, Pages i10–i12, <https://doi.org/10.1093/ecco-jcc/jjad212.0006>
15. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. 2021 Jun;160(7):2496-2508. doi: 10.1053/j.gastro.2021.04.022. PMID: 34051983; PMCID: PMC8988893.
16. Gordon H, Minozzi S, Kopylov U, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment, *Journal of Crohn's and Colitis*, 2024; <https://doi.org/10.1093/ecco-jcc/jjae091>
17. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology*. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001. PMID: 39572132.

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 Codes | ICD-10 Description  |
|--------------|---|
| K50.00       | Crohn's disease of small intestine without complications          |
| K50.011      | Crohn's disease of small intestine with rectal bleeding           |
| K50.012      | Crohn's disease of small intestine with intestinal obstruction    |
| K50.013      | Crohn's disease of small intestine with fistula                   |
| K50.014      | Crohn's disease of small intestine with abscess                   |
| K50.018      | Crohn's disease of small intestine with other complication        |
| K50.019      | Crohn's disease of small intestine with unspecified complications |
| K50.10       | Crohn's disease of large intestine without complications          |
| K50.111      | Crohn's disease of large intestine with rectal bleeding           |
| K50.112      | Crohn's disease of large intestine with intestinal obstruction    |
| K50.113      | Crohn's disease of large intestine with fistula                   |
| K50.114      | Crohn's disease of large intestine with abscess                   |
| K50.118      | Crohn's disease of large intestine with other complication        |

| ICD-10 Codes | ICD-10 Description   |
|--------------|--|
| K50.119      | Crohn's disease of large intestine with unspecified complications                |
| K50.80       | Crohn's disease of both small and large intestine without complications          |
| K50.811      | Crohn's disease of both small and large intestine with rectal bleeding           |
| K50.812      | Crohn's disease of both small and large intestine with intestinal obstruction    |
| K50.813      | Crohn's disease of both small and large intestine with fistula                   |
| K50.814      | Crohn's disease of both small and large intestine with abscess                   |
| K50.818      | Crohn's disease of both small and large intestine with other complication        |
| K50.819      | Crohn's disease of both small and large intestine with unspecified complications |
| K50.90       | Crohn's disease, unspecified, without complications                              |
| K50.911      | Crohn's disease, unspecified, with rectal bleeding                               |
| K50.912      | Crohn's disease, unspecified, with intestinal obstruction                        |
| K50.913      | Crohn's disease, unspecified, with fistula                                       |
| K50.914      | Crohn's disease, unspecified, with abscess                                       |
| K50.918      | Crohn's disease, unspecified, with other complication                            |
| K50.919      | Crohn's disease, unspecified, with unspecified complications                     |
| K51.00       | Ulcerative (chronic) pancolitis without complications                            |
| K51.011      | Ulcerative (chronic) pancolitis with rectal bleeding                             |
| K51.012      | Ulcerative (chronic) pancolitis with intestinal obstruction                      |
| K51.013      | Ulcerative (chronic) pancolitis with fistula                                     |
| K51.014      | Ulcerative (chronic) pancolitis with abscess                                     |
| K51.018      | Ulcerative (chronic) pancolitis with other complication                          |
| K51.019      | Ulcerative (chronic) pancolitis with unspecified complications                   |
| K51.20       | Ulcerative (chronic) proctitis without complications                             |
| K51.211      | Ulcerative (chronic) proctitis with rectal bleeding                              |
| K51.212      | Ulcerative (chronic) proctitis with intestinal obstruction                       |
| K51.213      | Ulcerative (chronic) proctitis with fistula                                      |
| K51.214      | Ulcerative (chronic) proctitis with abscess                                      |
| K51.218      | Ulcerative (chronic) proctitis with other complication                           |
| K51.219      | Ulcerative (chronic) proctitis with unspecified complications                    |
| K51.30       | Ulcerative (chronic) rectosigmoiditis without complications                      |
| K51.311      | Ulcerative (chronic) rectosigmoiditis with rectal bleeding                       |
| K51.312      | Ulcerative (chronic) rectosigmoiditis with intestinal obstruction                |
| K51.313      | Ulcerative (chronic) rectosigmoiditis with fistula                               |
| K51.314      | Ulcerative (chronic) rectosigmoiditis with abscess                               |

| ICD-10 Codes | ICD-10 Description   |
|--------------|--|
| K51.318      | Ulcerative (chronic) rectosigmoiditis with other complication        |
| K51.319      | Ulcerative (chronic) rectosigmoiditis with unspecified complications |
| K51.50       | Left sided colitis without complications                             |
| K51.511      | Left sided colitis with rectal bleeding                              |
| K51.512      | Left sided colitis with intestinal obstruction                       |
| K51.513      | Left sided colitis with fistula                                      |
| K51.514      | Left sided colitis with abscess                                      |
| K51.518      | Left sided colitis with other complication                           |
| K51.519      | Left sided colitis with unspecified complications                    |
| K51.80       | Other ulcerative colitis without complications                       |
| K51.811      | Other ulcerative colitis with rectal bleeding                        |
| K51.812      | Other ulcerative colitis with intestinal obstruction                 |
| K51.813      | Other ulcerative colitis with fistula                                |
| K51.814      | Other ulcerative colitis with abscess                                |
| K51.818      | Other ulcerative colitis with other complication                     |
| K51.819      | Other ulcerative colitis with unspecified complications              |
| K51.90       | Ulcerative colitis, unspecified, without complications               |
| K51.911      | Ulcerative colitis, unspecified with rectal bleeding                 |
| K51.912      | Ulcerative colitis, unspecified with intestinal obstruction          |
| K51.913      | Ulcerative colitis, unspecified with fistula                         |
| K51.914      | Ulcerative colitis, unspecified with abscess                         |
| K51.918      | Ulcerative colitis, unspecified with other complication              |
| K51.919      | Ulcerative colitis, unspecified with unspecified complications       |
| R19.7        | Diarrhea, unspecified  |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| <b>Medicare Part B Administrative Contractor (MAC) Jurisdictions</b> |   |   |
|--|---|---|
| <b>Jurisdiction</b>  | <b>Applicable State/US Territory</b>  | <b>Contractor</b>                                 |
| E (1)  | CA, HI, NV, AS, GU, CNMI  | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)  | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ  | Noridian Healthcare Solutions, LLC                |
| 5  | KS, NE, IA, MO  | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6  | MN, WI, IL  | National Government Services, Inc. (NGS)          |
| H (4 & 7)  | LA, AR, MS, TX, OK, CO, NM  | Novitas Solutions, Inc.                           |
| 8  | MI, IN  | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)  | FL, PR, VI  | First Coast Service Options, Inc.                 |
| J (10)   | TN, GA, AL  | Palmetto GBA                                      |
| M (11)   | NC, SC, WV, VA (excluding below)  | Palmetto GBA                                      |
| L (12)   | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |
| K (13 & 14)  | NY, CT, MA, RI, VT, ME, NH  | National Government Services, Inc. (NGS)          |
| 15   | KY, OH  | CGS Administrators, LLC                           |